News
MRNA
101.41
-0.58%
-0.59
Moderna stock on track for the eighth consecutive day of losses
Seeking Alpha · 10h ago
FOCUS-China's drugmakers can't sell mRNA shots but haven't quit yet
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants. Three Chinese companies came up with mRNA vaccines that won limited emergency approvals in Asia. China's drugmakers can't sell mRNA shots but haven't quit yet. Rival Moderna is setting up manufacturing in Shanghai and plans to launch 15 mRNA vaccines.
Reuters · 1d ago
Notable Thursday Option Activity: SMMT, MRNA, GME
NASDAQ · 1d ago
Moderna (MRNA) Stock Moves -0.34%: What You Should Know
NASDAQ · 2d ago
MODERNA: RECOMMENDS SHAREHOLDERS TO VOTE FOR ELECTION OF ALL THREE CLASS III DIRECTORS, EACH FOR THREE-YEAR TERM
Reuters · 3d ago
Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff
Johnson & Johnson reported a mixed first quarter report on Tuesday. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost in line with estimates. The healthcare company is also strengthening its position in the battle against cancer. JNJ reported a $13.1 billion acquisition of heart device firm Shockwave Medical Inc.
Benzinga · 3d ago
2 Artificial Intelligence (AI) in Healthcare Stocks to Buy and Hold for Great Long-Term Potential
These companies have gotten in on artificial intelligence early and could emerge as winners. The AI in healthcare market is expected to expand at a 48% growth rate to reach $148 billion by 2029. Moderna and Medtronic are two companies to buy and hold for their long-term potential. AI could help speed up drug development and improve patient outcomes.
The Motley Fool · 3d ago
Paramount, Etsy, Albemarle among most shorted S&P 500 stocks in March
Tech Consumer Paramount, Etsy, Albemarle among most shorted S&P 500 stocks in March. Bets against consumer discretionary stocks were the highest in the month of March. T-Mobile US, General Motors and Charter Communications had the largest short interest positions in the S&p 500.
Seeking Alpha · 4d ago
Analysts Forecast 10% Gains Ahead For VOT
NASDAQ · 4d ago
Novavax (NASDAQ:NVAX) Jumps Amid Activist Investor Push
TipRanks · 4d ago
Weekly Report: what happened at MRNA last week (0408-0412)?
Weekly Report · 4d ago
Hedge fund Shah Capital urges board shake-up at Novavax over struggling Covid vaccine, FT reports
Hedge fund Shah Capital urges board shake-up at Novavax over struggling Covid vaccine, FT reports. U.S.-based hedge fund wants two independent board directors for the biotech company. Shah Capital also wants a pivot in the sales strategy for its Covid-19 shot.
Reuters · 5d ago
2 Stocks Down 30% to Buy Right Now
Biotech companies Intellia Therapeutics and Moderna have each dropped about 30% over the past year. Both companies are in the field of CRISPR gene editing. The companies have plenty of catalysts ahead of them that could boost their long-term growth. These companies could be a good place to invest in these growth stocks now.
The Motley Fool · 5d ago
Pfizer wins pause on Moderna's COVID-19 patent lawsuit
Pfizer wins pause on Moderna's COVID-19 patent lawsuit claiming Pfizer copied its vaccine technology. Moderna accused Pfizer and BioNTech of violating its patent rights in messenger-RNA technology. The U.S. Patent Office will review two of the three Moderna patents at issue.
Reuters · 04/12 20:39
Short interest in S&P 500 health stocks rises, Moderna among most shorted companies in March
Short percentage in S&P 500’s healthcare companies surged in the end of March from February. Life science tools and services was the most shorted industry in the healthcare sector for March end. Average short interest in s&p 500 health stocks rises to 1.57% in March. Moderna among mostShorted companies in March with 6.42% of float.
Seeking Alpha · 04/12 17:17
Benjamin Graham Detailed Fundamental Analysis - MRNA
NASDAQ · 04/12 16:10
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
NASDAQ · 04/12 13:22
1 New Green Flag for Moderna and Merck Stock
Moderna is developing a personalized cancer vaccine for head and neck cancers in conjunction with Merck. In a phase 1 trial, two patients with the disease responded well to the vaccine. The vaccine could be approved for sale in a handful of years. Moderna is the company behind the Spikevax coronavirus vaccine.
The Motley Fool · 04/12 12:45
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
NASDAQ · 04/11 22:00
Moderna (NASDAQ:MRNA) Postpones Plans of Vaccine Plant in Kenya
TipRanks · 04/11 15:59
More
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.